explore -WSS

explore

author：fashion 2025-10-02 21:35:48 - browse：164

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： How to save PrEP access — and even expand it

hotspot

WSS

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Pfizer's Covid pill remains 89% effective in final analysis, company says

Did the public have the right to know Arthur Ashe had AIDS?

7 people shot in DC, police say

Sports medicine is finally prioritizing gender equality

Wikipedia

explore

focus

Continuity nursing helped my family in our darkest PICU moments

New air purifier tech could be key to improving indoor air quality

Cancer drug shortages should be causing more outrage

PhRMA sues HHS over Medicare drug price negotiation

BioMarin wins approval for gene therapy to treat hemophilia A

Anesthesiologist group: stop taking Ozempic before surgery

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Hepatitis C has a cure — but many Americans still lack access to it

In Memoriam: Notable people who died in 2023

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

entertainment

Pfizer's Covid pill remains 89% effective in final analysis, company says

Affirmative action in medical school literally saved lives

RaDonda Vaught case: a double standard for nurses, physicians

Brain 'hot spot' may explain why African Americans feel greater pain

Wildfire smoke exposes gaps in outdoor worker protections

Supreme Court strikes down use of affirmative action

knowledge

hotspot

focus

hotspot